JP2013534227A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013534227A5 JP2013534227A5 JP2013524362A JP2013524362A JP2013534227A5 JP 2013534227 A5 JP2013534227 A5 JP 2013534227A5 JP 2013524362 A JP2013524362 A JP 2013524362A JP 2013524362 A JP2013524362 A JP 2013524362A JP 2013534227 A5 JP2013534227 A5 JP 2013534227A5
- Authority
- JP
- Japan
- Prior art keywords
- nasal
- nose
- powder
- ingested
- sucking
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000001331 nose Anatomy 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102010034699.3 | 2010-08-18 | ||
| DE102010034699A DE102010034699A1 (de) | 2010-08-18 | 2010-08-18 | Pyrimidinderivate |
| PCT/EP2011/003597 WO2012022408A1 (de) | 2010-08-18 | 2011-07-19 | Pyrimidinderivate als fak inhibitoren |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016153334A Division JP6441861B2 (ja) | 2010-08-18 | 2016-08-04 | Ｆａｋ阻害剤としてのピリミジン誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013534227A JP2013534227A (ja) | 2013-09-02 |
| JP2013534227A5 true JP2013534227A5 (enExample) | 2016-01-07 |
| JP6049617B2 JP6049617B2 (ja) | 2016-12-21 |
Family
ID=44504442
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013524362A Expired - Fee Related JP6049617B2 (ja) | 2010-08-18 | 2011-07-19 | Ｆａｋ阻害剤としてのピリミジン誘導体 |
| JP2016153334A Expired - Fee Related JP6441861B2 (ja) | 2010-08-18 | 2016-08-04 | Ｆａｋ阻害剤としてのピリミジン誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016153334A Expired - Fee Related JP6441861B2 (ja) | 2010-08-18 | 2016-08-04 | Ｆａｋ阻害剤としてのピリミジン誘導体 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8906916B2 (enExample) |
| EP (1) | EP2606034B1 (enExample) |
| JP (2) | JP6049617B2 (enExample) |
| CN (1) | CN103052627B (enExample) |
| AR (1) | AR082722A1 (enExample) |
| AU (1) | AU2011291110B2 (enExample) |
| CA (1) | CA2808540C (enExample) |
| DE (1) | DE102010034699A1 (enExample) |
| DK (1) | DK2606034T3 (enExample) |
| ES (1) | ES2572740T3 (enExample) |
| HR (1) | HRP20160562T1 (enExample) |
| HU (1) | HUE027846T2 (enExample) |
| IL (1) | IL224751A (enExample) |
| PL (1) | PL2606034T3 (enExample) |
| RS (1) | RS54882B1 (enExample) |
| SI (1) | SI2606034T1 (enExample) |
| WO (1) | WO2012022408A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102010034699A1 (de) * | 2010-08-18 | 2012-02-23 | Merck Patent Gmbh | Pyrimidinderivate |
| US9174946B2 (en) | 2011-02-17 | 2015-11-03 | Cancer Therapeutics Crc Pty Ltd | Selective FAK inhibitors |
| EP2675793B1 (en) | 2011-02-17 | 2018-08-08 | Cancer Therapeutics Crc Pty Limited | Fak inhibitors |
| US9013997B2 (en) * | 2012-06-01 | 2015-04-21 | Broadcom Corporation | System for performing distributed data cut-through |
| WO2014027199A1 (en) * | 2012-08-14 | 2014-02-20 | Cancer Therapeutics Crc Pty Ltd | Fak and flt3 inhibitors |
| US9266864B2 (en) | 2012-08-17 | 2016-02-23 | Cancer Therapeutics Crc Pty Limited | VEGFR3 inhibitors |
| US20160009686A1 (en) * | 2012-08-17 | 2016-01-14 | Cancer Therapeutics Crc Pty Limited | Vegfr3 inhibitors |
| TW201412740A (zh) * | 2012-09-20 | 2014-04-01 | Bayer Pharma AG | 經取代之吡咯并嘧啶胺基苯并噻唑酮 |
| JPWO2014174745A1 (ja) * | 2013-04-26 | 2017-02-23 | 国立大学法人京都大学 | Ｅｇ５阻害剤 |
| US10106834B2 (en) | 2013-10-09 | 2018-10-23 | The General Hospital Corporation | Methods of diagnosing and treating B cell acute lymphoblastic leukemia |
| WO2015123722A1 (en) * | 2014-02-19 | 2015-08-27 | Bionomics Limited | Inhibitors |
| EP4070795A1 (en) * | 2014-08-25 | 2022-10-12 | Salk Institute for Biological Studies | Novel ulk1 inhibitors and methods using same |
| WO2019117813A1 (en) * | 2017-12-15 | 2019-06-20 | National University Of Singapore | Focal adhesion kinase targeted therapeutics for the treatment of glaucoma and fibrosis |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| US6184225B1 (en) | 1996-02-13 | 2001-02-06 | Zeneca Limited | Quinazoline derivatives as VEGF inhibitors |
| DE69709319T2 (de) | 1996-03-05 | 2002-08-14 | Astrazeneca Ab, Soedertaelje | 4-anilinochinazolin derivate |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| CA2406979A1 (en) | 2000-05-31 | 2001-12-06 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| HUP0301742A3 (en) | 2000-07-07 | 2005-08-29 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors, process for producing them, pharmaceutical compositions containing them and their use |
| BR0112224A (pt) | 2000-07-07 | 2003-06-10 | Angiogene Pharm Ltd | Composto, composição farmacêutica, uso de um composto ou de um sal, solvato ou pró-droga farmaceuticamente aceitável do mesmo, e, processo para preparar um composto |
| DE50212771D1 (de) * | 2001-10-17 | 2008-10-23 | Boehringer Ingelheim Pharma | Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung |
| JP2005526831A (ja) | 2002-04-09 | 2005-09-08 | アステックス テクノロジー リミテッド | 医薬化合物 |
| WO2004056807A1 (en) | 2002-12-20 | 2004-07-08 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
| UA80767C2 (en) * | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| CN101189529A (zh) * | 2005-04-08 | 2008-05-28 | 拜尔药品公司 | 嘧啶衍生物 |
| CN103588704B (zh) | 2007-03-16 | 2016-09-14 | 斯克里普斯研究学院 | 粘着斑激酶抑制剂 |
| JP2011512413A (ja) | 2008-02-19 | 2011-04-21 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | Ｆａｋの阻害剤としてのアニリノピリジン |
| EP2361248B1 (en) * | 2008-06-27 | 2018-09-19 | Celgene CAR LLC | Heteroaryl compounds and uses thereof |
| UY32240A (es) | 2008-11-14 | 2010-06-30 | Boeringer Ingelheim Kg | Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones. |
| AR074209A1 (es) * | 2008-11-24 | 2010-12-29 | Boehringer Ingelheim Int | Derivados de pirimidina utiles para el tratamiento del cancer |
| DE102010034699A1 (de) * | 2010-08-18 | 2012-02-23 | Merck Patent Gmbh | Pyrimidinderivate |
| EP2675793B1 (en) * | 2011-02-17 | 2018-08-08 | Cancer Therapeutics Crc Pty Limited | Fak inhibitors |
| US9174946B2 (en) * | 2011-02-17 | 2015-11-03 | Cancer Therapeutics Crc Pty Ltd | Selective FAK inhibitors |
-
2010
- 2010-08-18 DE DE102010034699A patent/DE102010034699A1/de not_active Withdrawn
-
2011
- 2011-07-19 DK DK11743438.1T patent/DK2606034T3/en active
- 2011-07-19 SI SI201130848A patent/SI2606034T1/sl unknown
- 2011-07-19 AU AU2011291110A patent/AU2011291110B2/en not_active Ceased
- 2011-07-19 PL PL11743438T patent/PL2606034T3/pl unknown
- 2011-07-19 RS RS20160420A patent/RS54882B1/sr unknown
- 2011-07-19 CN CN201180039922.8A patent/CN103052627B/zh not_active Expired - Fee Related
- 2011-07-19 HU HUE11743438A patent/HUE027846T2/en unknown
- 2011-07-19 US US13/817,251 patent/US8906916B2/en not_active Expired - Fee Related
- 2011-07-19 ES ES11743438.1T patent/ES2572740T3/es active Active
- 2011-07-19 CA CA2808540A patent/CA2808540C/en not_active Expired - Fee Related
- 2011-07-19 HR HRP20160562TT patent/HRP20160562T1/hr unknown
- 2011-07-19 WO PCT/EP2011/003597 patent/WO2012022408A1/de not_active Ceased
- 2011-07-19 EP EP11743438.1A patent/EP2606034B1/de active Active
- 2011-07-19 JP JP2013524362A patent/JP6049617B2/ja not_active Expired - Fee Related
- 2011-08-18 AR ARP110102997A patent/AR082722A1/es unknown
-
2013
- 2013-02-17 IL IL224751A patent/IL224751A/en active IP Right Grant
-
2016
- 2016-08-04 JP JP2016153334A patent/JP6441861B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014509313A5 (enExample) | ||
| JP2013534227A5 (enExample) | ||
| JP2014526447A5 (enExample) | ||
| JP2013544781A5 (enExample) | ||
| JP2013541565A5 (enExample) | ||
| JP2015505541A5 (enExample) | ||
| Doktorovova et al. | Preclinical safety of solid lipid nanoparticles and nanostructured lipid carriers: Current evidence from in vitro and in vivo evaluation | |
| RU2015121091A (ru) | Порошки для ингаляции с ультранизкой плотностью | |
| EA201590286A1 (ru) | Аэрозольное ингаляционное устройство | |
| MX371521B (es) | Sistema de inhalacion de polvo seco. | |
| BR112013022249B8 (pt) | Dispositivo de distribuição de droga nasal | |
| WO2014012069A3 (en) | Dry powder drug delivery systems and methods | |
| ATE527976T1 (de) | Vorrichtung zur lagerung, unmittelbaren zubereitung und verabreichung eines wirkstoffes | |
| EA201591729A1 (ru) | Пригодные для вдыхания агломераты частиц пористого носителя и тонкоизмельченного лекарственного средства | |
| WO2010029441A3 (en) | Nasal delivery | |
| WO2012051426A3 (en) | Aggregate nanoparticulate medicament formulations, manufacture and use thereof | |
| WO2012024595A3 (en) | Circumferential aerosol device for delivering drugs to olfactory epithelium and brain | |
| WO2013155201A3 (en) | Spray ejector mechanisms and devices providing charge isolation and controllable droplet charge, and low dosage volume opthalmic administration | |
| WO2013090841A3 (en) | Aerosolization apparatus for inhalation profile-independent drug delivery | |
| MY191380A (en) | Stabilized fixed dose drug composition having mometasone and olopatadine | |
| UA107499C2 (uk) | Склад сухого порошку, який містить антимускариновий засіб | |
| WO2013038268A8 (en) | Tamper resistant immediate release formulations | |
| JP2020527377A5 (enExample) | ||
| JP2014530231A5 (enExample) | ||
| MY160652A (en) | Pharmaceutical composition for oral administration |